TRICHOSANTHIN TREATMENT OF HIV-INDUCED IMMUNE DYSREGULATION

被引:36
作者
MAYER, RA [1 ]
SERGIOS, PA [1 ]
COONAN, K [1 ]
OBRIEN, L [1 ]
机构
[1] RA MAYER CLIN,DEPT RES & DEV,N MIAMI,FL
关键词
AIDS; ANTIVIRAL ACTIVITY; CD4+ LYMPHOCYTES; RIBOSOME-INACTIVATING PROTEINS; TRICHOSANTHIN;
D O I
10.1111/j.1365-2362.1992.tb01944.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Twenty patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC) or asymptomatic HIV infection (HIV+) were given 20 mcg kg-3 trichosanthin (TCS; 'Compound Q'), a ribosome-inactivating protein with in vitro antiviral activity against human immunodeficiency virus (HIV) once every four weeks for up to 12 weeks. With the concurrent administration of prostaglandin inhibitors, the drug was moderately well tolerated, with most subjects experiencing mild arthralgia, hives and malaise. Additionally, four patients experienced neurological complications which resolved spontaneously without intervention. Four of 20 subjects in this open label pilot study showed progressive although transient reductions in viral activity as measured by p-24 antigen level decreases. Subjects also experienced decreases in levels Of beta-2-Microglobulin. Ten HIV+ and healthy ARC subjects demonstrated improved immunological status as measured by significant increases in percentage of CD4+ cells and augmentations in delayed hypersensitivity reactions. Eight of 20 subjects reported improved appetites and increased energy levels. The group as a whole had a weight gain of 3.2 kg. Eight of 20 subjects who presented with persistent generalized lymphadenopathy exhibited a marked diminution in the size of their lymph nodes after the first treatment. No subject who presented with oral candidiasis experienced an improvement in that condition. We conclude that, in the short term, TCS seems to have the ability to reduce viral activity and improve certain symptoms in healthy ARC patients and HIV+ asymptomatics although it may not be able to restore immune competence in persons with advanced AIDS or poor prognosis ARC. Additionally, the drug may pose a special risk for patients with HIV-related dementia.
引用
收藏
页码:113 / 122
页数:10
相关论文
共 27 条
[1]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[2]  
CUI J, 1987, SHANGHAI 2ND MED U, V1, P37
[3]  
FISHL MA, 1987, NEW ENGL J MED, V317, P185
[4]   FREQUENT DETECTION AND ISOLATION OF CYTOPATHIC RETROVIRUSES (HTLV-III) FROM PATIENTS WITH AIDS AND AT RISK FOR AIDS [J].
GALLO, RC ;
SALAHUDDIN, SZ ;
POPOVIC, M ;
SHEARER, GM ;
KAPLAN, M ;
HAYNES, BF ;
PALKER, TJ ;
REDFIELD, R ;
OLESKE, J ;
SAFAI, B ;
WHITE, G ;
FOSTER, P ;
MARKHAM, PD .
SCIENCE, 1984, 224 (4648) :500-503
[5]  
GOEDERT JJ, 1984, LANCET, V2, P711
[6]   3-YEAR INCIDENCE OF AIDS IN 5 COHORTS OF HTLV-III-INFECTED RISK GROUP MEMBERS [J].
GOEDERT, JJ ;
BIGGAR, RJ ;
WEISS, SH ;
EYSTER, ME ;
MELBYE, M ;
WILSON, S ;
GINZBURG, HM ;
GROSSMAN, RJ ;
DIGIOLA, RA ;
SANCHEZ, WC ;
GIRON, JA ;
EBBESEN, P ;
GALLO, RC ;
BLATTNER, WA .
SCIENCE, 1986, 231 (4741) :992-995
[7]  
GOTTLIEB M, 5TH INT C AIDS MONTR
[8]  
HEYES MP, 5TH INT C AIDS MONTR
[9]   PROSPECTS OF THERAPY FOR INFECTIONS WITH HUMAN T-LYMPHOTROPIC VIRUS TYPE-III [J].
HIRSCH, MS ;
KAPLAN, JC .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (05) :750-755
[10]   THE SAFETY AND PHARMACOKINETICS OF GLQ223 IN SUBJECTS WITH AIDS AND AIDS-RELATED COMPLEX - A PHASE-I STUDY [J].
KAHN, JO ;
KAPLAN, LD ;
GAMBERTOGLIO, JG ;
BREDESEN, D ;
ARRI, CJ ;
TURIN, L ;
KIBORT, T ;
WILLIAMS, RL ;
LIFSON, JD ;
VOLBERDING, PA .
AIDS, 1990, 4 (12) :1197-1204